You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 1, 2026

NEOMYCIN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Neomycin, and what generic alternatives are available?

Neomycin is a drug marketed by Pharmafair, Watson Labs, Xgen Pharms, Bausch And Lomb, Padagis Us, Sciegen Pharms Inc, Alcon Pharms Ltd, Ipharm, Amneal, Sandoz, Saptalis Pharms, Aarxion Anda Hlding, Bristol Myers Squibb, Chartwell Molecular, Lannett, Lilly, Pharmobedient, Roxane, Teva, Fougera, and Pharmaderm. and is included in forty-four NDAs.

The generic ingredient in NEOMYCIN is neomycin sulfate; triamcinolone acetonide. There are nineteen drug master file entries for this compound. Additional details are available on the neomycin sulfate; triamcinolone acetonide profile page.

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for NEOMYCIN?
  • What are the global sales for NEOMYCIN?
  • What is Average Wholesale Price for NEOMYCIN?
Summary for NEOMYCIN
US Patents:0
Applicants:21
NDAs:44
Drug Prices: Drug price information for NEOMYCIN
DailyMed Link:NEOMYCIN at DailyMed
Drug patent expirations by year for NEOMYCIN
Drug Prices for NEOMYCIN

See drug prices for NEOMYCIN

US Patents and Regulatory Information for NEOMYCIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pharmaderm NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE neomycin sulfate; triamcinolone acetonide CREAM;TOPICAL 062595-001 Jul 21, 1986 DISCN No No ⤷  Get Started Free ⤷  Get Started Free ⤷  Get Started Free
Sandoz NEOMYCIN SULFATE neomycin sulfate TABLET;ORAL 061586-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Get Started Free ⤷  Get Started Free ⤷  Get Started Free
Lannett NEOMYCIN SULFATE neomycin sulfate TABLET;ORAL 060607-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Get Started Free ⤷  Get Started Free ⤷  Get Started Free
Teva NEOMYCIN SULFATE neomycin sulfate TABLET;ORAL 060304-001 Approved Prior to Jan 1, 1982 AA RX No Yes ⤷  Get Started Free ⤷  Get Started Free ⤷  Get Started Free
Lilly NEOMYCIN SULFATE neomycin sulfate TABLET;ORAL 060385-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Get Started Free ⤷  Get Started Free ⤷  Get Started Free
Pharmafair NEOMYCIN & POLYMYXIN B SULFATES & BACITRACIN ZINC & HYDROCORTISONE bacitracin zinc; hydrocortisone; neomycin sulfate; polymyxin b sulfate OINTMENT;TOPICAL 062381-001 Sep 6, 1985 DISCN No No ⤷  Get Started Free ⤷  Get Started Free ⤷  Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.